Takeda's livtencitytm (maribavir) approved by u.s. fda as the first and only treatment for people ages 12 and older with post-transplant cytomegalovirus (cmv), refractory (with or without genotypic resistance) to conventional antiviral therapies

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the u.s. food and drug administration (fda) has approved livtencity™ (maribavir) for the treatment of adults and pediatric patients (12 years of age or older and weighing at least 35 kg) with post-transplant cytomegalovirus (cmv) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofo
TAK Ratings Summary
TAK Quant Ranking